Camurus AB (publ)

LSE:0RD1 Stock Report

Market Cap: SEK 35.2b

Camurus Valuation

Is 0RD1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RD1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 2.05k
Fair Value
72.8% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: 0RD1 (SEK596) is trading below our estimate of fair value (SEK2038.8)

Significantly Below Fair Value: 0RD1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RD1?

Key metric: As 0RD1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RD1. This is calculated by dividing 0RD1's market cap by their current earnings.
What is 0RD1's PE Ratio?
PE Ratio122.9x
EarningsSEK 266.21m
Market CapSEK 35.17b

Price to Earnings Ratio vs Peers

How does 0RD1's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RD1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.2x
HIK Hikma Pharmaceuticals
20.6x11.0%UK£4.8b
ANCR Animalcare Group
37.4xn/aUK£173.2m
GSK GSK
22.2x20.8%UK£55.6b
AZN AstraZeneca
32.6x17.0%UK£171.3b
0RD1 Camurus
132.1x82.9%SEK 35.2b

Price-To-Earnings vs Peers: 0RD1 is expensive based on its Price-To-Earnings Ratio (132.1x) compared to the peer average (28.2x).

Price to Earnings Ratio vs Industry

How does 0RD1's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0RD1 122.9xIndustry Avg. 21.0xNo. of Companies8PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0RD1 is expensive based on its Price-To-Earnings Ratio (132.1x) compared to the European Pharmaceuticals industry average (21x).

Price to Earnings Ratio vs Fair Ratio

What is 0RD1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RD1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio122.9x
Fair PE Ratio93x

Price-To-Earnings vs Fair Ratio: 0RD1 is expensive based on its Price-To-Earnings Ratio (132.1x) compared to the estimated Fair Price-To-Earnings Ratio (88.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RD1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 596.00
SEK 745.00
+25.0%
2.8%SEK 768.00SEK 710.00n/a6
Jan ’26SEK 563.85
SEK 745.00
+32.1%
2.8%SEK 768.00SEK 710.00n/a6
Dec ’25SEK 564.50
SEK 745.00
+32.0%
2.8%SEK 768.00SEK 710.00n/a6
Nov ’25SEK 597.50
SEK 753.33
+26.1%
1.7%SEK 773.00SEK 730.00n/a6
Oct ’25SEK 651.00
SEK 742.67
+14.1%
2.8%SEK 770.00SEK 710.00n/a6
Sep ’25SEK 712.50
SEK 742.67
+4.2%
2.8%SEK 770.00SEK 710.00n/a6
Aug ’25SEK 687.50
SEK 742.67
+8.0%
2.8%SEK 770.00SEK 710.00n/a6
Jul ’25SEK 603.01
SEK 621.50
+3.1%
9.4%SEK 690.00SEK 500.00n/a6
Jun ’25SEK 577.67
SEK 612.33
+6.0%
12.7%SEK 690.00SEK 445.00n/a6
May ’25SEK 497.03
SEK 577.17
+16.1%
14.4%SEK 690.00SEK 445.00n/a6
Apr ’25SEK 504.73
SEK 577.17
+14.4%
14.4%SEK 690.00SEK 445.00n/a6
Mar ’25SEK 468.75
SEK 573.00
+22.2%
15.7%SEK 690.00SEK 420.00n/a6
Feb ’25SEK 522.19
SEK 549.83
+5.3%
20.8%SEK 690.00SEK 420.00n/a6
Jan ’25SEK 537.90
SEK 508.00
-5.6%
19.8%SEK 650.00SEK 420.00SEK 563.856
Dec ’24SEK 463.92
SEK 471.33
+1.6%
17.3%SEK 650.00SEK 420.00SEK 564.506
Nov ’24SEK 333.78
SEK 351.33
+5.3%
6.7%SEK 380.00SEK 320.00SEK 597.506
Oct ’24SEK 311.04
SEK 320.50
+3.0%
17.4%SEK 380.00SEK 205.00SEK 651.006
Sep ’24SEK 295.01
SEK 320.50
+8.6%
17.4%SEK 380.00SEK 205.00SEK 712.506
Aug ’24SEK 294.96
SEK 320.50
+8.7%
17.4%SEK 380.00SEK 205.00SEK 687.506
Jul ’24SEK 278.59
SEK 298.17
+7.0%
14.4%SEK 332.00SEK 205.00SEK 603.016
Jun ’24SEK 279.80
SEK 298.17
+6.6%
14.4%SEK 332.00SEK 205.00SEK 577.676
May ’24SEK 231.96
SEK 284.67
+22.7%
14.1%SEK 320.00SEK 205.00SEK 497.036
Apr ’24SEK 218.00
SEK 284.67
+30.6%
14.1%SEK 320.00SEK 205.00SEK 504.736
Mar ’24SEK 225.60
SEK 284.67
+26.2%
14.1%SEK 320.00SEK 205.00SEK 468.756
Feb ’24SEK 249.40
SEK 310.00
+24.3%
5.5%SEK 330.00SEK 280.00SEK 522.195
Jan ’24SEK 252.60
SEK 305.00
+20.7%
5.1%SEK 320.00SEK 280.00SEK 537.904
Analyst Price Target
Consensus Narrative from 6 Analysts
SEK 745.00
Fair Value
25.3% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 18:26
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Camurus AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Oscar Haffen LammBryan Garnier & Co
Alexandru CogutBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB